Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inbrija
Pharma
Acorda files for bankruptcy, inks $185M asset deal to Merz
Merz, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug Amprya.
Zoey Becker
Apr 9, 2024 8:29am
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Jan 11, 2024 1:15pm
Fighting talk: Acorda gets combative in new Parkinson's campaign
Aug 3, 2023 8:00am
Slow Inbrija launch forces Acorda to slash $800M sales hopes
Feb 13, 2020 10:52am
Acorda's sales team switches gears to promote Inbrija
Jan 15, 2019 11:20am
Acorda pulls off delayed Parkinson’s approval for Inbrija
Dec 26, 2018 2:18pm